$KMDA

Kamada Ltd

  • NASDAQ
  • Health Technology
  • Biotechnology

PRICE

$5.17 -

Extented Hours

VOLUME

28,466

DAY RANGE

5.16 - 5.2929

52 WEEK

4.22 - 6.96

Join Discuss about KMDA with like-minded investors

profile
@maletone #StockTraders.NET
recently

$KMDA getting lit

98 Replies 10 👍 13 🔥

profile
@FillTheGapToZero #StockTraders.NET
recently

KMDA expensive so I just went with SONN

113 Replies 7 👍 14 🔥

profile
@maletone #StockTraders.NET
recently

$KMDA is available

127 Replies 13 👍 9 🔥

profile
@Neptune5045 #StockTraders.NET
recently

Also $KZIA $ADMA worth watching > @Neptune5045 said: $SONN $LMNL $KMDA familiar names

129 Replies 9 👍 6 🔥

profile
@Neptune5045 #StockTraders.NET
recently

$SONN $LMNL $KMDA familiar names

111 Replies 12 👍 11 🔥

profile
@truublue #droscrew
recently

wonder what that means for companies like $kmda

109 Replies 6 👍 7 🔥

profile
@truublue #droscrew
recently

buying a little more $kmda equity

47 Replies 10 👍 10 🔥

Key Metrics

Market Cap

236.54 M

Beta

0.67

Avg. Volume

33.36 K

Shares Outstanding

44.80 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-10

Next Dividend Date

Company Information

Kamada Ltd. (the 'Company') is a global specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company's strategy is focused on driving profitable growth from its current commercial products, its plasma-derived development pipeline and its manufacturing expertise, while evolving into a vertically integrated plasma-derived company. The Company's two leading commercial products are GLASSIA® and KEDRRAB®. GLASSIA was the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the FDA. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited ('Takeda') and in other countries through local distributors. Pursuant to an agreement with Takeda, the Company will continue to produce GLASSIA for Takeda through 2021 and Takeda will initiate its own production of GLASSIA for the U.S. market in 2021, at which point Takeda will commence payment of royalties to the Company until 2040. KEDRAB is an FDA approved anti-rabies immune globulin (Human) for post-exposure prophylaxis treatment. KEDRAB is being marketed in the U.S. through a strategic partnership with Kedrion S.p.A. The Company has additional four plasma-derived products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has two leading development programs; a plasma-derived hyperimmune immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19) and an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added nine biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2025. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company's lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

Website:

HQ: ,

Related News